Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 85,804 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 1 Clear all
Active, not recruiting Phase 3 Interventional Results available

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

NCT05257408
View directory record Official record
Conditions
Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Interventions
Relacorilant 150 mg, Nab-paclitaxel 80 mg/m^2, Nab-paclitaxel 100 mg/m^2
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
44
States / cities
Phoenix, Arizona • Tucson, Arizona • Irvine, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 2:19 PM EDT
Terminated Phase 3 Interventional

XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors

NCT00090025
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
becatecarin, 5-Fluorouracil Plus Leucovorin
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
27
States / cities
Birmingham, Alabama • Long Beach, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2009 · Synced Oct 30, 2026, 2:19 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

NCT01522976
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions
Azacitidine, Laboratory Biomarker Analysis, Lenalidomide, Vorinostat
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
280
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 217 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 2 Interventional

Dexamethasone in Cryptococcal Meningitis

NCT00000776
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Flucytosine, Fluconazole, Amphotericin B, Dexamethasone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
13
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

Desensitization and Cognitive Therapy in General Anxiety.

NCT00951340
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Cognitive behavioral therapy (CBT), Emotional processing and interpersonal therapy, Listening therapy
Other · Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Timeline
1996 – 1998
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 30, 2026, 2:19 PM EDT
Withdrawn No phase listed Observational

Assessment of Quality of Life and Satisfaction With Medical Care of Pediatric Type 1 Diabetes Mellitus Patients

NCT00450489
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
6 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 2 Interventional

Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer

NCT00052689
View directory record Official record
Conditions
Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer
Interventions
bortezomib, gemcitabine hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 1Phase 2 Interventional

Acute Nicotine Gum and Tinnitus Loudness in Non-Smoking Adults

NCT07772089
View directory record Official record
Conditions
Tinnitus, Chronic Subjective Tinnitus
Interventions
Nicotine polacrilex gum 4 mg, Placebo gum
Drug · Other
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 2:19 PM EDT
Not yet recruiting Phase 2 Interventional

A Study to Investigate Pivmecillinam Versus Nitrofurantoin in Female Adolescents 12 to Less Than 18 Years of Age With Uncomplicated Urinary Tract Infection

NCT07871968
View directory record Official record
Conditions
Uncomplicated Urinary Tract Infections
Interventions
Pivya (Pivmecillinam 185 mg), Nitrofurantoin 100 mg (nitrofurantoin monohydrate/macrocrystalline capsule)
Drug
Lead sponsor
Alembic Therapeutics
Industry
Eligibility
12 Years to 17 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dearborn Heights, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

Buffered Lidocaine for Loop Electrosurgical Excision Procedures (LEEPs)

NCT01405768
View directory record Official record
Conditions
Uterine Cervical Dysplasia
Interventions
sodium bicarbonate buffered lidocaine, Non-buffered lidocaine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Phytochemicals on Aspects of Cognitive Performance

NCT02167750
View directory record Official record
Conditions
Cognitive Performance
Interventions
Cherry Flavored Beverage
Other
Lead sponsor
PepsiCo Global R&D
Industry
Eligibility
17 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Oct 30, 2026, 2:19 PM EDT
Completed No phase listed Observational

Using Magnetic Resonance Imaging to Evaluate Heart Vessel Function After Angioplasty or Stent Placement Procedures

NCT00692991
View directory record Official record
Conditions
Myocardial Infarction, Angina, Unstable, Cardiomyopathy, Hypertrophic
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

Full-time Bangerter Filters Versus Part-time Daily Patching for Moderate Amblyopia in Children

NCT00525174
View directory record Official record
Conditions
Amblyopia
Interventions
Bangerter filters, Patching, Near activities
Device · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 9 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 30, 2026, 2:19 PM EDT
Suspended Phase 1 Interventional

Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization

NCT05264974
View directory record Official record
Conditions
Melanoma, Soft Tissue Sarcoma
Interventions
Autologous total tumor mRNA loaded DOTAP liposome vaccine
Biological
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 30, 2026, 2:19 PM EDT
Recruiting No phase listed Observational

Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed Therapies

NCT06532474
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years to 20 Years
Enrollment
24 participants
Timeline
2025 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney Function

NCT00596518
View directory record Official record
Conditions
Renal Insufficiency, Chronic
Interventions
PF-00734200
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 77 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 4 Interventional Results available

Methadone Versus Morphine for Orthopedic Surgery Patients

NCT00892606
View directory record Official record
Conditions
Fracture, Pain, Postoperative
Interventions
Methadone, Morphine
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 30, 2026, 2:19 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Collaborative Care Intervention for Cancer Patients and Their Family Caregivers -LITE

NCT05601206
View directory record Official record
Conditions
Cancer, Depression, Fatigue, Pain, Sleep
Interventions
Stepped collaborative care intervention, Enhanced Usual Care
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2028 – 2032
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

NCT03681184
View directory record Official record
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Interventions
Placebo, Lumasiran
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
5
States / cities
San Diego, California • Jacksonville, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

NCT00082433
View directory record Official record
Conditions
Cancer, Breast Cancer
Interventions
Ixabepilone + Capecitabine, Capecitabine
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
34
States / cities
Tucson, Arizona • Beverly Hills, California • Corona, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification

NCT01664247
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, placebo, liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
67
States / cities
Anaheim, California • Concord, California • Escondido, California + 59 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 30, 2026, 2:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Field Usability Study of Eclipse Mask

NCT05559047
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Eclipse mask
Device
Lead sponsor
Bleep, LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Asheville, North Carolina • Huntersville, North Carolina • Murfreesboro, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 30, 2026, 2:19 PM EDT
Recruiting Phase 1 Interventional

Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell

NCT07062549
View directory record Official record
Conditions
Renal Cell Carcinoma (Kidney Cancer)
Interventions
111In-XYIMSR-01
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 30, 2026, 2:19 PM EDT
Terminated Phase 1 Interventional

Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)

NCT01434849
View directory record Official record
Conditions
Infantile Hemangioma, Very Low Birth Weight Infants
Interventions
topical 0.5% Timolol maleate, Control (placebo) group
Drug
Lead sponsor
Alice K. Gong
Other
Eligibility
Up to 6 Months
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Oct 30, 2026, 2:19 PM EDT